Musbau Tajudeen, Al-Bubseeree Bahaa
Hematology, Victoria Hospital Kirkcaldy, Kirkcaldy, GBR.
Cureus. 2025 May 8;17(5):e83730. doi: 10.7759/cureus.83730. eCollection 2025 May.
Multiple myeloma (MM) and acute myeloid leukemia (AML) are malignant clonal disorders with divergent lineages. It is extremely uncommon for both conditions to be diagnosed simultaneously in a patient. This case report examines the uncommon occurrence of AML alongside MM in a 60-year-old male patient. The diagnosis of AML was based on the World Health Organization benchmark, and the patient was categorized as having AML with myelodysplastic defining molecular changes. The patient completed the first cycle of induction chemotherapy with daunorubicin, cytarabine, and gemtuzumab ozogamicin but had a poor response, indicating refractory disease. A bone marrow aspiration following treatment revealed 30% blasts and 11% plasma cells. These plasma cells were CD138 positive and were not present at the time of diagnosis. Additionally, M-protein was detected in the blood. Intermediate chemotherapy with venetoclax and azacitidine was considered, as the patient was not fit for the combination of fludarabine, cytarabine, granulocyte colony-stimulating factor, and idarubicin. Furthermore, the myeloma was not treated as he was not fit for any intensive chemotherapy. The patient's disease was refractory despite four cycles of venetoclax and azacitidine, as evident by residual blasts of 32% in the bone marrow.
多发性骨髓瘤(MM)和急性髓系白血病(AML)是具有不同谱系的恶性克隆性疾病。在一名患者中同时诊断出这两种疾病极为罕见。本病例报告探讨了一名60岁男性患者中AML与MM同时发生的罕见情况。AML的诊断基于世界卫生组织的标准,该患者被归类为具有骨髓增生异常定义分子变化的AML。患者完成了柔红霉素、阿糖胞苷和吉妥珠单抗奥佐米星的第一个诱导化疗周期,但反应不佳,表明疾病难治。治疗后的骨髓穿刺显示有30%的原始细胞和11%的浆细胞。这些浆细胞CD138阳性,在诊断时并不存在。此外,血液中检测到M蛋白。考虑使用维奈克拉和阿扎胞苷进行中间化疗,因为该患者不适合使用氟达拉滨、阿糖胞苷、粒细胞集落刺激因子和伊达比星的联合治疗。此外,由于他不适合任何强化化疗,所以未对骨髓瘤进行治疗。尽管进行了四个周期的维奈克拉和阿扎胞苷治疗,患者的疾病仍难治,骨髓中残留32%的原始细胞即为明证。